HEALTH CATALYST ($HCAT) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of $0.04 per share, beating estimates of $0.03 by $0.01. The company also reported revenue of $70,490,000, beating estimates of $70,354,061 by $135,939.
Stock price change since market close: -27.83%
You can see Quiver Quantitative's $HCAT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HEALTH CATALYST Hedge Fund Activity
We have seen 65 institutional investors add shares of HEALTH CATALYST stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CDC FINANCIAL, INC. added 2,305,008 shares (+57.6%) to their portfolio in Q1 2026, for an estimated $2,927,360
- PALOGIC VALUE MANAGEMENT, L.P. added 1,626,559 shares (+128.1%) to their portfolio in Q1 2026, for an estimated $2,065,729
- NEPSIS INC. added 1,099,898 shares (+58.6%) to their portfolio in Q2 2026, for an estimated $2,188,797
- MILLENNIUM MANAGEMENT LLC removed 1,084,843 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,377,750
- ACADIAN ASSET MANAGEMENT LLC removed 819,525 shares (-87.9%) from their portfolio in Q1 2026, for an estimated $1,040,796
- RA CAPITAL MANAGEMENT, L.P. removed 793,749 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,008,061
- CAPTION MANAGEMENT, LLC added 771,886 shares (+inf%) to their portfolio in Q1 2026, for an estimated $980,295
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HEALTH CATALYST Price Targets
Multiple analysts have issued price targets for $HCAT recently. We have seen 6 analysts offer price targets for $HCAT in the last 6 months, with a median target of $1.875.
Here are some recent targets:
- Stan Berenshteyn from Wells Fargo set a target price of $1.75 on 06/26/2026
- Jeff Garro from Stephens & Co. set a target price of $1.75 on 05/12/2026
- Sarah James from Cantor Fitzgerald set a target price of $3.0 on 03/13/2026
- David Grossman from Stifel set a target price of $2.0 on 03/13/2026
- Richard Close from Canaccord Genuity set a target price of $2.0 on 03/13/2026
- Daniel Grosslight from Citigroup set a target price of $1.75 on 03/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
